TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00062439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: During induction:50 mg/m2,IV on Days 1, 8, 29 \& 36. In any appropriate vehicle over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
Study: NCT00476125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary manipulation ketogenic diet
Description: Subjects will consume a ketogenic diet for 3 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Manipulation - 12 day ketogenic diet
Description: Subjects will consume a ketogenic diet for 12 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16 Hour Fast
Description: Subjects will fast for 16 hours.
Study: NCT03212911

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
Study: NCT04308421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red light
Description: Low irradiation 650 nm +/- 5 nm red light
Study: NCT02352025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
Study: NCT04291651

Intervention type: OTHER
Intervention: Survey
Description: There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.
Study: NCT04024150

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
Study: NCT03511807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical
Description: For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic
Description: For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds).
Study: NCT01527149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous HDC-ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03350997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial 2 Exercise
Description: During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial 1 Exercise
Description: During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
Study: NCT02610296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1002
Description: IV injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study: NCT02096445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted neurocognitive therapy of hand function
Description: 2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neurocognitive rehabilitation
Description: Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
Study: NCT02749396

Intervention type: DRUG
Intervention: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Extavia (interferon beta-1b), Novartis Pharma AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Extavia (interferon beta-1b), Novartis Pharma AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Rebif (interferon beta-1a), Merck Serono Europe Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Rebif (interferon beta-1a), Merck Serono Europe Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Plegridy (peginterferon beta-1a), Biogen Idec Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Avonex (interferon beta-1a), Biogen Idec Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: Avonex (interferon beta-1a), Biogen Idec Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT01765166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSGRIN-Parent Guide
Description: All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSGRIN-Parent Guide
Description: All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSGRIN-Parent Guide
Description: All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSGRIN-Parent Guide
Description: All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
Study: NCT02749396

Intervention type: DRUG
Intervention: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: DRUG
Intervention: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)

Intervention type: OTHER
Intervention: No MSDMDs therapy (control)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study: NCT01277016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMDex
Description: BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle.
Study: NCT04078841

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReaLife+ (RLP)
Description: RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Brown powder
Description: Brown powder Inert brown powder to look similar to RLP
Study: NCT00521950

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TPMT genotyping; Drug: azathioprine or 6-mercaptopurine
Description: Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine (AZA) or 6-mercaptopurine (6-MP)
Description: Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Study: NCT01781936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Study: NCT04196686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR/AR
Description: VR/AR headset with either passive or active content such as playing a game or watching a movie

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR/AR
Description: VR/AR headset with either passive or active content such as playing a game or watching a movie

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Bath
Description: Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Bath
Description: Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
Study: NCT02135861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI scans
Description: Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI scans
Description: Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI scans
Description: Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
Study: NCT03670823

Intervention type: DEVICE
Intervention: SIEMENS PRISMA MRI
Description: Collect data on brain activation from different methods

Intervention type: DEVICE
Intervention: SIEMENS PRISMA MRI
Description: Collect data on brain activation from different methods
Study: NCT03821896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Cards for Adolescents and Goal-Setting
Description: The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-Setting
Description: Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
Study: NCT04514887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild intraoperative hyperventilation
Description: Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
Study: NCT03379818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape training intervention
Description: This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific word training
Description: In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
Study: NCT03606434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: 30 minutes of intermittent hypoxia
Study: NCT01873066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time CGM
Description: Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real-time CGM
Description: Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study: NCT00560066

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-derived influenza vaccine
Description: 1 dose of 0.5 mL in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-derived influenza vaccine
Description: 1 dose of 0.5 mL in the deltoid region of the non-dominant arm
Study: NCT01945060

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: heart rate Control to Range System (hrCTR) using DiAs Platform
Description: Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate Control to Range System (hrCTR) using DiAs Platform
Description: Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DiAs Control-to-Range System not informed for heart rate
Description: Not informing system of heart rate during exercise.
Study: NCT05923671

Intervention type: DIAGNOSTIC_TEST
Intervention: Histological analysis
Description: Histological staining of gingival biopsies with haematoxylin-eosin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histological analysis
Description: Histological staining of gingival biopsies with haematoxylin-eosin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical analysis
Description: Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical analysis
Description: Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
Study: NCT05915650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Carry out pain neuroscience education intervention for TKA patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Education
Description: Carry out routine education intervention for TKA patients
Study: NCT00972205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-1(Registered Trademark)
Description: CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tc 99m sestamibi
Description: 20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.